Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2009-09-08
2011-11-15
Gussow, Anne M. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007210
Reexamination Certificate
active
08058016
ABSTRACT:
A human antibody fragment, which antibody or fragment:(i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and(ii) binds to human plaques.
REFERENCES:
patent: 5807978 (1998-09-01), Kokolus et al.
patent: 6046381 (2000-04-01), Mucke et al.
patent: 6107045 (2000-08-01), Koren et al.
patent: 6787519 (2004-09-01), Huang et al.
patent: 2002/0155426 (2002-10-01), Cordell et al.
patent: 2004/0157267 (2004-08-01), Huang
patent: 1434053 (2004-06-01), None
patent: 94/09155 (1994-04-01), None
patent: 2004/011943 (2004-02-01), None
Aizawa et al. “Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brians: A possible role for apolipoprotein E in Alzheimer's disease” Brain Res. 768:208-214 (1997).
Bi et al. “Rapid induction of intraneuronal neurofibrillary tangles in apolipoprotein E-deficient mice” Proc. Natl. Acad. Sci. USA 98:8832-8837 (2001).
Biodesign International, “Mouse anti-apolipoprotein E monoclonal antibody” Catalog No. H61529M (2002).
Bury et al. “1. Apoliprotein quantification by ELISA: Technical aspects and clinical applications” Rev. Immuno. Technol. 1:1-25 (1998).
Carlsson et al. “Clinical relevance of the quantification of apolipoprotein E in cerebrospinal fluid” Clin. Chimica Acta 196:167-176 (1991).
Casset et al. “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design” Biochem. Biophys. Res. Comm. 307:198-205 (2003).
Castano et al. “Apolipoprotein E carboxyl-terminal fragments are complexed to amyloids A and L” J. Biol. Chem. 270:17610-17615 (1995).
Chemicon International “Goat anti-apolipoprotein E polyclonal antibody” Catalog No. AB947 (2001).
Chemicon International “Mouse anti-apolipoprotein E monoclonal antibody” Catalog No. MAB1062 (2002).
Chen et al. “Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen” J. Mol. Biol. 293:865-881 (1999).
Cho et al. “Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Aβ aggregation” J. Neuropathol. Exp. Neurol. 160:342-349 (2001).
Davies et al. “Affinity improvement of single antibody VH domains: Residues in all three hypervariable regions affect antigen binding” Immunotechnol. 2:169-179 (1996).
De Pascalis et al. “ Grafting of abbreviated complementarity-determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody” J. Immunol. 169:3076-3084 (2002).
Demeester et al. “Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin: Cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease” J. Lipid Res. 41:963-974 (2000).
Fujita et al. “Apolipoprotein E is found in astrocytes but not in microglia in the normal mouse brain” Neurosci. Res. 35:123-133 (1999).
Golabek et al. “Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid β-peptide with the N-terminal, receptor binding domain of apolipoprotein E” Biophys. J. 79:1008-1015 (2000).
Harris et al. “Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice” Proc. Natl. Acad. Sci. USA 100:10966-10971 (2003).
Hock et al. “Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease” Neuron 38:547-554 (2003).
Holm et al. Functional mapping and single chain construction of the anti-ctytokeratin 8 monoclonal antibody TS1. Mol. Immunol. 44:1075-1084 (2007).
Huang et al. “Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons” Proc. Natl. Acad. Sci. USA 98:8838-8843 (2001).
Klezovitch et al. “Structural determinants in the C-terminal domain of apolipoprotein E mediating binding to the protein core of human aortic biglycan” J. Biol. Chem. 275:18913-18918 (2000).
Labeur et al. “Immunological assays of apolipoproteins in plasma: Methods and instrumentation” Clin. Chem. 36:591-597 (1990).
Lederman et al. “A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody OKT4” Mol. Immunol. 28:1171-1181 (1991).
Lee et al. “Microbial cell-surface display” Trends Biotechnol. 21:45-52 (2003).
Li et al. “B-endorphin omission analogs: Dissociation of immunoreactivity from other biological activities” Proc. Nat. Acad. Sci. 77:3211-3214 (1980).
Lynch et al. “Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response” J. Neuroimmunol. 114:107-113 (2001).
Maccallum et al. “Antibody-antigen interactions: Contact analysis and binding site topography” J. Mol. Biol. 262:732-745 (1996).
Mahley et al. “Apolipoprotein E structure, function, and possible roles in Alzheimer's disease” Ann. N. Y. Acad. Sci. 777:139-145 (1996).
Namba et al. “Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease” Brain Res. 541:163-166 (1991).
Marcel et al. “Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects” J. Clin. Invest. 85:10-17 (1990).
Milne et al. “Characterization of monoclonal antibodies against human apolipoprotein E” J. Clin. Invest. 68:111-117 (1981).
Näslund et al. “Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain” Neuron 15:219-228 (1995).
Nishida et al. “Apolipoproteins J and E co-localise with amyloid in gelatinous drop-like and lattice type I corneal dystrophies” Br. J. Ophthalmol. 83:1178-1182 (1999).
Perugini et al. “Self-association of human apolipoprotein E3 and E4 in the presence and absence of phospholipid” J. Biol. Chem. 275:36758-36765 (2000).
Pillot et al. “β-Amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: Relevance to Alzheimer's disease” J. Neurochem. 72:230-237 (1999).
Rudikoff et al. “Single amino acid substitution altering antigen-binding specificity” Proc. Nat. Acad. Sci. 79:1979-1983 (1982).
Sadowski et al. “Inhibition of apolipoprotein E binding to amyloid— beta decreases fibril formation and deposition in vitro and in vivo” Meeting of the Society for Neuroscience, Abstract No. 666.6 (2003).
Saunders et al. “The role of apolipoprotein E in Alzheimer's disease: Pharmacogenomic target selection” Biochim. Biophys. Acta 1502:85-94 (2000).
Sparrow et al. “Apolipoprotein E: Phospholipid binding studies with synthetic peptides from the carboxyl terminus” Biochem. 31:1065-1068 (1992).
Terai et al. “Apolipoprotein E deposition and astrogliosis are associated with maturation of β-amyloid plaques in βAPPswe transgenic mouse: Implications for the pathogenesis of Alzheimer's disease” Brain Res. 900:48-56 (2001).
Vajdos et al. “Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis” J. Mol. Biol. 320:415-428 (2002).
Yamada et al. “Further characterization of a monoclonal antibody recognizing apolipoprotein E peptides in amyloid deposits” Annals Clin. Lab. Sci. 27:276-281 (1997).
Yamada et al. “A monoclonal antibody recognizing apolipoprotein E peptides in systemic amyloid deposit&#x
Andersson Christin V.
Goldschmidt Tom
Henderikx Maria
Hoet Rene
Hoogenboom Henricus
Astrazeneca AB
Dyax Corporation
Gussow Anne M.
Nixon & Vanderhye P.C.
LandOfFree
Methods of using an antibody that binds to apolipoprotein e does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using an antibody that binds to apolipoprotein e, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using an antibody that binds to apolipoprotein e will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4296771